Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2018 07:04 ET | Source: Aptose Biosciences, Inc.

APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

SAN DIEGO and TORONTO, May 31, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
May 17, 2018 11:43 ET | Source: Aptose Biosciences, Inc.

Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association

SAN DIEGO and TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
May 10, 2018 16:00 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the First Quarter Ended March 31, 2018

SAN DIEGO and TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
May 07, 2018 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Exercises Early Option for CG-806 License From CrystalGenomics

SAN DIEGO and SEOUL, South Korea, May 07, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) and CrystalGenomics, Inc. (KOSDAQ:083790) today announced that Aptose exercised its...
May 01, 2018 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018

SAN DIEGO and TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
April 25, 2018 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Appointment of Caroline M. Loewy to Board of Directors

SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
April 24, 2018 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018

SAN DIEGO and TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
April 17, 2018 14:00 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting

CHICAGO and SAN DIEGO and TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data exploring the mechanism of...
April 16, 2018 07:30 ET | Source: Aptose Biosciences, Inc.

OHSU and Aptose Present New CG’806 Preclinical Data at 2018 AACR Annual Meeting

CHICAGO and PORTLAND, Ore. and SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Oregon Health & Science University (OHSU) Knight Cancer Institute and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS)...
April 16, 2018 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting

CHICAGO and SAN DIEGO and TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating the robust...